Study on the interaction of the dopamine agonist α-dihydroergocryptine with the pharmacokinetics of digoxin

Arzneimittel-Forschung/Drug Research

Volumn 50, Issue 7, 2000, Pages 591-596

  Retzow, Angelika ^a   Althaus, Michael ^a   De Mey, Christian ^b   Mazur, Dago ^c   Vens Cappell, Bernhard ^c  

^a ALK SCHERAX Arzneimittel GmbH   (Germany)

^b Appl Clinical Pharmacology Services   (Germany)

^c Phoenix Intl Life Sci Hamburg GmbH   (Germany)

Author keywords

Almirid ; CAS 14271 05 7; Digoxin; Dopamine agonists; Dihydroergocryptine, clinical pharmacokinetics, drug interaction

Indexed keywords

DIGOXIN; DIHYDROERGOCRYPTINE; DOPAMINE RECEPTOR STIMULATING AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG POTENTIATION; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MALE; NORMAL HUMAN; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; RHINITIS; VERTIGO;

EID: 0033943235     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1300256     Document Type: Article

References (21)

1. [1] Markstein, R., Dopamine receptor profile of co-dergocrine (Hydergine®) and its components, Eur. J. Pharmacol. 86, 145 (1983)
2. [2] Markstein, R., Closse, A., Frick, W., Interaction of ergot alkaloids and their combination (co-dergocrine) with a-adrenoceptors in the CNS. Eur. J. Pharmacol. 93, 159 (1983)
3. [3] Soskic, V., Petrovic, I., Effects of several ergosines on adenylate cyclase activity in synaptosomal membranes of the bovine caudate nucleus. J. Pharm. Pharmacol. 38, 128 (1986)
4. [4] Grognet, J. M., Istin, M., Zanotti, A. et al., Pharmacokinetics of a-dihydroergokryptine in rats after intravenous and oral administration. Arzneim.-Forsch./Drug Res. 41 (I), 689 (1991)
5. [5] Grognet, J. M., Istin, M., Zanotti, A. et al., Pharmacokinetics of α-dihydroergokryptine in monkeys after oral administration. Drugs Exp. Clin. Res. 17, 309 (1991)
6. [6] Canonico, P. L., Relative bioequivalence of three oral forms of daverium: capsules, tablets, oral drops. Study with a single dose of 20 mg in male and female volunteers. Internal study report, Poli Industria Chimica, Milan (1993)
7. [7] Mas-Chamberlin, C., Bromet, N., Olgiati, V et al., Metabolism study of dihydro-α-ergocryptine, 9, 10-[9, 10-3H(N)] in rat and human hepatocyte cultures and rat, monkey, and human microsomes. Am. J. Ther. 4, 291 (1997)
8. 3H-α-dihydroergocryptine mesylate. Am. J. Ther. 3, 553 (1996)
9. [9] Zanotti, A., Coppi, G., Mailand, F., in: Progress in Gynecology and Obstetrics, A. R. Genazzani, F. Petraglia, A. Volpe (eds.), pp 491-499, The Parthenon Publishing Group, Carnforth, UK (1990)
10. [10] Scarzella, L., Cantello, R., Delsedime, M. et al., Clinical trial on the therapeutic activity of dihydroergocryptine in parkinsonism: Preliminary results. Curr. Ther. Res. 38, 432 (1985)
11. [11] Piolti, R., Apolonio, I., Frattola, L., in: Proceedings 17th meeting L.I.M.P.E., Padova 1990, A. Agnoli, L. Battistin (eds.), pp 287-297, Publicatione Guanella, Roma (1991)
12. [12] Martignoni, E., Pacchetti, C., Sibilla, L. et al., Dihydroergocryptine in the treatment of Parkinson's disease: A six months' double-blind clinical trial. Clin. Neuropharmacol. 1, 78 (1991)
13. [13] Battistin, L., Bardin, P. G., Ferro-Milone, F. et al., alpha-dihydroergocryptine in Parkinson's disease: a multicentre randomized double-blind parallel group study. Acta Neurol. Scand. 99, 36 (1999)
14. [14] Roden, D. M., in: Goodman and Gilman's The Pharmacological basis of Therapeutics, 9th edn., J. G. Hardman, L. E. Limbird, P. B. Molinoff et al. (eds.), pp. 839-874, McGraw-Hill, New York (1996)
15. [15] Nies, A. S., Spielberg, S. P., in: Goodman and Gilman's The Pharmacological basis of Therapeutics, 9th edn. J. G. Hardman, L. E. Limbird, P. B. Molinoff et al. (eds.) pp. 43-63, McGraw-Hill, New York (1996)
16. [16] Marcus, F. I., Pharmacokinetic interactions between digoxin and other drugs. J. Am. Coll. Cardiol. 5, 82A (1985)
17. [17] Cockcroft, D. W., Gault, M. H., Prediction of creatinine clearance from serum creatinine. Nephron 16, 31 (1976)
18. [18] SAS Procedures Guide, Release 6.03 Edition. The GLM Procedure, p. 519, SAS Institute Inc., Cary, NC (1988)
19. [19] SAS Procedures Guide, Release 6.03 Edition. The UNIVARIATE procedure, p. 405, SAS Institute Inc., Cary NC (1988)
20. [20] Antman, E. M., Arnold, J. M. O., Friedman, P. L. et al., Pharmacokinetic drug interactions between digoxin and antiarrhythmic agents and calcium blocking agents: an appraisal of study methodology. Cardiovasc. Drug Ther. 1, 183 (1987)
21. [21] Reuning, R. H., Geraets, D. R., in: Applied Pharmacokinetics: Principles of therapeutic drug monitoring. 2nd edn. W. E. Evans, J. J. Schentag, W. J. Jusko et al. (eds.). Applied Therapeutics Inc., Spokane, US (1987)